acgood Thursday, 09/06/12 11:27:04 PM Re: iwfal post# 148299 0 Post # of 223688 The SNTA trial is not blinded. The company sure had the data in hand for weeks last time as they talked the stock from 4 to 8 w/ wall street analysts in June. No reason to believe anything different is happening this time. Two key notes for me from Stifel - final PFS data for phase 3 already pushed back from 1h2014 to 2014 (and didn't reiterate 2014 NDA) - didn't show/discuss the subgroup data - are they reversing and considering phase 3 in all adeno? mentioned OS benefit in all adeno specifically this time Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.